In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary

1st May 2025 Uncategorised 0

Just as Eli Lilly appeared to be gaining an edge over its metabolic medicine rival Novo Nordisk in the U.S. obesity market, Novo has locked in a new formulary access deal that could give its star weight loss drug Wegovy a major advantage over its Lilly counterpart.

More: In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary
Source: fierce